Table 6 |
|||||
|
Endothelial function during treatment in the longitudinal study |
|||||
|
Baseline |
2 weeks |
12 weeks |
Treatment effect |
Degrees of freedom |
|
|
|
|||||
|
Microvascular function |
|||||
|
Endothelium-dependent (Ach%) |
314 ± 214 |
423 ± 250a |
348 ± 209b |
F = 5.09, P = 0.01 |
2, 21 |
|
Endothelium-independent (SNP%) |
247 ± 126 |
284 ± 147 |
261 ± 152 |
F = 1.18, P = 0.32 |
2, 21 |
|
Macrovascular function |
|||||
|
Endothelium-dependent (FMD%) |
9.4 ± 6.8 |
12.0 ± 10.0 |
12.0 ± 8.1 |
F = 1.60, P = 0.21 |
2, 19 |
|
Endothelium-independent (GTN%) |
22 ± 7.4 |
23 ± 7.2 |
24 ± 7.2 |
F = 0.31, P = 0.74 |
2, 19 |
|
|
|||||
|
Results are expressed as mean ± standard deviation. aDifferent from baseline. bDifferent from 2 weeks. Ach, acetylcholine; FMD, flow-mediated dilatation; GTN, glyceryl trinitrate-mediated dilatation; SNP, sodium nitroprusside. |
|||||
|
Sandoo et al. Arthritis Research & Therapy 2012 14:R117 doi:10.1186/ar3847 |
|||||